High-performance sensor solutions supplier ams and in vitro diagnostic medical devices manufacturer Senova have partnered to develop a rapid antibody test for Covid-19.
A specially designed sensor module based on the ams AS7341L spectral sensor solution is said to enable spectrally resolved readout of lateral flow immune assays.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The ams spectral sensor technology was successfully tested in combination with Senova´s commercially available serological IgG/M Covid-19 assay.
Based on this, the companies are entering a partnership to combine the read-out technology of ams with the lateral flow-test capabilities of Senova.
Both companies have agreed on developing a disposable electronic lateral flow test towards testing for immunity against the SARS-CoV-2 virus based on antibody detection.
ams Advanced Optical Sensors Division EVP commented Jennifer Zhao said: “ams’ innovation through miniaturised and cost-effective spectral sensor technology is more valuable than ever for healthcare applications.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“Enabling rapid test devices to detect colourimetric and fluorescence information through a tiny, yet powerful, optical sensor supports wide-spread testing for viruses and antibodies at disposable cost levels. With this technology, we hope to contribute to the fight against the pandemic the world is facing right now.”
In addition, ams will partner with healthcare manufacturing solutions provider Jabil Healthcare to integrate its sensor technology into a high-volume turnkey module, featuring a Bluetooth connection. The partnership will enable the company to attain manufacturing scale in an accelerated timeframe.
ams, Senova and Jabil are anticipated to roll out the CE medical-certified, disposable test kits by September.
Senova CEO Hans Hermann Söffing said: “This collaborative project is a great opportunity to provide a new generation of point-of-care tests, which combine fundamental improvements in accuracy and superior handling at the same time.
“A digital Covid-19 antibody test kit will be the next important element to support healthcare providers worldwide in the current situation.”
